

研究成果の刊行に関する一覧表

(松本 美富士)

著書

1. 松本美富士：本邦線維筋痛症の臨床疫学像．日本線維筋痛症学会編、線維筋痛症診療ガイドライン 2013、日本醫事新報出版社、東京、2013.
2. 松本美富士：診断基準．日本線維筋痛症学会編、線維筋痛症診療ガイドライン 2013、日本醫事新報出版社、東京、2013.
3. 松本美富士：鑑別診断、その他：、慢性疲労症候群、脊髄液減少症．日本線維筋痛症学会編、線維筋痛症診療ガイドライン 2013、日本醫事新報出版社、東京、2013.

雑誌

1. 松本美富士：線維筋痛症の up to date. リウマチ科, 2012; 47(4): 436-445.

(植田 弘師)

著書

1. Ueda H, Matsunaga H and Sebok K. Halder. Prothymosin -A Novel Endogenous Neuroprotective Polypeptide against Ischemic Damages. In: Neuropeptides in Neuroprotection and Neuroregeneration. CRC Press,2012, pp128-143.
2. 植田弘師、永井潤：慢性疼痛創薬標的としてのリゾホスファチジン酸、遺伝子医学 M00K24号, 2013 (印刷中)

雑誌

1. Ma L, Nagai J, Sekino Y, Goto Y, Nakahira S, Ueda H: Single application of A2 NTX, a botulinum toxin A2 subunit, prevents chronic pain over long periods in both diabetic and spinal cord injury-induced neuropathic pain models. J Pharmacol Sci. 119(3):282-286,2012
2. Halder SK, Matsunaga H, Ueda H:Neuron-specific non-classical release of prothymosin alpha: a novel neuroprotective damage-associated molecular patterns. J Neurochem. 123(2):262-75,2012
3. Halder SK , Yano R, Jerold Chun, Ueda H:Involvement of LPA1 receptor signaling in cerebral ischemia-induced neuropathic pain. Neuroscience. (in press)
4. 植田弘師、松下洋輔：神経障害性痛の責任分子と治療創薬について.ペインクリニック 33(7):911-922, 2012
5. Ueda H, Matsunaga H, Halder, SK: Prothymosin plays multifunctional cell robustness roles in genomic, epigenetic, and nongenomic mechanisms. Ann N Y Acad Sci.

1269(1):34-43, 2012

6. Ueda H, Matsunaga H, Olaposi Omotuyi I, Nagai J: Lysophosphatidic acid: Chemical signature of neuropathic pain. *Biochim Biophys Acta.* 1831(1)61-73, 2013

7. 植田弘師、永井潤：神経障害性疼痛における生理活性脂質 LPA の生合成機構および病態機能、*ペインクリニック* 33(11): 1575-1583, 2012

(中島 利博)

雑誌

1. Yagishita N, Aratani S, Leach C, Amano T, Yamano Y, Nakatani K, Nishioka K, Nakajima T : RING-finger type E3 ubiquitin ligase inhibitors as novel candidates for the treatment of rheumatoid arthritis. *Int. J. Mol. Med.* 30: 1281-6, 2012.

2. Tanabe C, Maeda T, Zou K, Liu J, Liu S, Nakajima T, Komano H : The ubiquitin ligase synoviolin up-regulates amyloid production by targeting a negative regulator of -secretase, Rer1, for degradation. *J Biol Chem.* 28: 287(53):44203-11, 2012.

3. Usui C, Hatta K, Aratani S, Yagishita N, Nishioka K, Kanazawa T, Ito K, Yamano Y, Nakamura H, Nakajima T, Nishioka K : The Japanese version of the modified ACR Preliminary Diagnostic Criteria for Fibromyalgia and the Fibromyalgia Symptom Scale: reliability and validity *Mod. Rheumatol.* 2012. 2012 Sep 24. [Epub ahead of print]

(岡 寛)

著書

1. 岡 寛：薬物療法、神経因性疼痛改善薬と副症状、合併症に対する治療。日本線維筋痛症学会編、*線維筋痛症診療ガイドライン 2013*、日本醫事新報出版社、東京、2013。

雑誌

1. Hiroyoshi Ohta, Hiroshi Oka, Chie Usui, Masayuki Ohkura, Makoto Suzuki and Kusuki Nishioka : A randomized, double-blind, multicenter, placebo-controlled phase trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia : *Arthritis Research & Therapy* 2012, 14:R217

2. Hiroyoshi Ohta, Hiroshi Oka, Chie Usui, Masayuki Ohkura, Makoto Suzuki, Kusuki Nishioka : An open-label long-term phase extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia: *Springer Link, Modern Rheumatology*, 2013 in press.

3. 岡寛：本邦における線維筋痛症の治療の現状、*東京医科大学雑誌*、第 71 巻 1 号、

(行岡 正雄)

著書

行岡正雄：鑑別診断、線維筋痛症と整形外科的疾患の鑑別。日本線維筋痛症学会編、線維筋痛症診療ガイドライン 2013、日本醫事新報出版社、東京、2013。

雑誌

1. Mie Fusama, Hideko Nakahara, Masao Yukioka, Keiji Maeda, et al. Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab. *Modern Rheumatol.* 2013; 23(2): 276-283

2. Yukinori Okada, Chikashi Terao, Masao Yukioka, Yusuke Nakamura, Kazuhiko Yamamoto, et al.: Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. *Nat Genet* 2012; 44(5):.511-516.

(宮岡 等、宮地 英雄)

著書

1.宮岡 等：鑑別診断、線維筋痛症と精神疾患の鑑別。日本線維筋痛症学会編、線維筋痛症診療ガイドライン 2013、日本醫事新報出版社、東京、2013。

雑誌

1. 宮岡等:Escitalopram・QT 延長症候群・意識消失.精神科治療学、2012; 27(11):1502-150.

2. 乾真美、山本賢司、宮地英雄、宮地伸吾、山本宏明、飯田諭宜、湯川泰一、宮岡等：うつ病の身体症状と精神症状の関連について。精神医学、2012; 54(11):1151-1158.

3. 宮地伸吾、宮岡等：精神症状の見方と対応、うつ。臨牀と研究、2012;89(9):11-15.

4. Takashi Hasegawa, Toshiyuki Koya, Takuro Sakagami, Yoshiyuki Muramatsu, Kumiko Muramatsu, Hiroshi Kagamu, Ichiroh Mashima, Masaaki Arakawa, Fumitake Gejyo, Hitoshi Miyaoka, Kunitoshi Kamijima, Ichiei Narita, Eiichi Suzuki: Analysis of Depression in Asthmatic Patients Using the Japanese Version of Patient Health Questionnaire-9. *Allergology International* 2012; 6(3): 475-487.

5. 中島香澄、岩満優美、大石智、村上尚美、宮岡等：精神医療において期待される心理士の役割 - 精神科医・心療内科医を対象としたアンケート調査。日本社会精神医学会雑誌、2012;21(3): 278-287.

6. 宮岡等、宮地英雄、宮岡佳子：セネストパチーの典型例。精神科治療学、2012; 27(7):919-922.

7. 新井久稔、山本賢司、井上勝夫、丸香奈恵、塚原敦子、宮岡等：入院による血液透析を必要とした精神障害者の臨床的特徴について。精神医学、2012;54(4):411-417.

8. Hisatoshi Arai, Megumi Takahashi, Motoki Yutani, Taichiro Ikeda, Satoru Oishi,

Hitoshi Miyaoka: Relationship among white matter hyperintensity, arterial stiffness, associated diseases, and lifestyle in late-onset Alzheimer's disease patients. *The Kitasato Medical Journal* 2012; 42 (1):83-90.

9. 宮岡 等; 身体表現性障害 総説身体表現性障害とは. *こころの科学*, 2013; 167: 10-13.

10. 宮地英雄: 身体表現性障害、持続性身体表現性疼痛障害. *こころの科学*, 2013; 167:36-39.

(横田 俊平)

著書

横田俊平: 小児の線維筋痛症の診療と治療. 日本線維筋痛症学会編、線維筋痛症診療ガイドライン 2013、日本醫事新報出版社、東京、2013.

雑誌

1)宮前 多佳子, 菊地 雅子, 野澤 智, 金高 太一, 木澤 敏毅, 今川 智之, 横田 俊平: 顕著な摂食障害・体重減少を呈した若年性線維筋痛症症例の検討. *日本小児科学会雑誌* 2012; 116 巻2号 Page407.

2)Momomura M, Miyamae T, Nozawa T, Kikuchi M, Kizawa T, Imagawa T, Drouot L, Jouen F, Boyer O, Yokota S.: Serum levels of anti-SRP54 antibodies reflect disease activity of necrotizing myopathy in a child treated effectively with combinatorial methyl prednisolone pulses and plasma exchanges followed by intravenous cyclophosphamide. *Modern Rheumatol.* 2012 Nov 3. [Epub ahead of print]

3)Yokota S, Nishikomori R, Takada H, Kikuchi M, Nozawa T, Kanetaka T, Kizawa T, Miyamae T, Mori M, Heike T, Hara T, Imagawa T.: Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan. *Modern Rheumatol.* 2012 Oct 20. [Epub ahead of print]

4)Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, Mori M, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S.: Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. *Clin Rheumatol.* 2012 Oct 2. [Epub ahead of print]

5)Harada T, Ito S, Mori M, Yokota S.: Anatomical condition mimicking superior mesenteric artery syndrome might cause duodenal involvement in Henoch-Schönlein purpura. *Pediatr Int.* 2012;54(4):579. doi: 10.1111/j. 1442-200X.2012.03659.x.

6)Inaba Y, Ozawa R, Aoki C, Imagawa T, Mori M, Hara R, Miyamae T, Saito T, Yokota S.: Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis. *Modern Rheumatol.* 2012 Jul 13.

[Epub ahead of print]

7) Ichikawa Y, Yokoyama U, Iwamoto M, Oshikawa J, Okumura S, Sato M, Yokota S, Masuda M, Asou T, Ishikawa Y.: Inhibition of phosphodi- esterase type 3 dilates the rat ductus arteriosus without inducing intimal thickening. *Circ J.* 2012 Sep 25;76(10):2456-64. Epub 2012 Jul 6.

8) Takenoue Y, Kaneko T, Miyamae T, Mori M, Yokota S. " Influence of outdoor NO₂ exposure on asthma in childhood: Meta-analysis. *Pediatr Int.* 2012 May 29. doi: 10.1111/j. 1442-200X.2012.03674.x. [Epub ahead of print]

9) Yuzurihara SS, Ao K, Hara T, Tanaka F, Mori M, Kikuchi N, Kai S, Yokota S.: Human parechovirus-3 infection in nine neonates and infants presenting symptoms of hemophagocytic lymphohistiocytosis. *J Infect Chemother.* 2012 May 10. [Epub ahead of print]

10) Kishi T, Miyamae T, Hara R, Nakajima S, Imagawa T, Mori M, Yokota S.: Clinical analysis of 50 children with juvenile dermatomyositis. *Modern Rheumatol.* 2012 Apr 22. [Epub ahead of print]

11) Kawabata T, Komaki H, Saito T, Saito Y, Nakagawa E, Sugai K, Sasaki M, Hayashi YK, Nishino I, Momomura M, Kizawa T, Imagawa T, Yokota S.: A pediatric patient with myopathy associated with antibodies to a signal recognition particle. *Brain Dev.* 2012 Nov; 34(10):877-80. doi: 10.1016/j.braindev.2012. 02.009. Epub 2012 Mar 19.

12) Yokota S, Kikuchi M, Nozawa T, Kizawa T, Kanetaka T, Miyamae T, Mori MA, Nishikomori R, Takata H, Heike T, Hara T, Imagawa T.: An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab. *Nihon Rinsho Meneki Gakkai Kaishi.* 2012; 35(1):23-9. Review. Japanese.

13) Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.: Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. *J Rheumatol.* 2012 Apr;39(4):864-7. Epub 2012 Feb 15.

14) Shinoki T, Hara R, Kaneko U, Miyamae T, Imagawa T, Mori M, Yokota S.: Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. *Mod Rheumatol.* 2012 Nov;22(6):871-6. doi: 10.1007/s10165-012-0595 -z. Epub 2012 Feb 11.

15) Yokota S, Imagawa T, Murata T, Tomiita M, Itoh Y, Fujikawa S, Takei S, Mori M.: Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan. *Modern Rheumatol.* 2012 Aug;22(4):491-7. Epub 2012 Jan 19.

16) Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Higuchi R, Kawano Y, Yokota S, Sugiyama N, Yuasa H, Fletcher T, Wajdula JS.: Safety and efficacy of long-term

etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan. *Mod Rheumatol*. 2012 Sep; 22(5):720-6. doi: 10.1007/s10165-011-0578-5. Epub 2012 Jan 4.

17)Goto H, Yanagimachi M, Goto S, Takeuchi M, Kato H, Yokosuka T, Kajiwara R, Yokota S.:Methylated chrysin reduced cell proliferation, but antagonized cytotoxicity of other anticancer drugs in acute lymphoblastic leukemia. *Anticancer Drugs*. 2012 Apr; 23(4): 417-25. doi:10.1097/CAD.0b013e32834fb731.

18)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, Seki K, Taguri M, Yokota S, Ishiwada N.:Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. *Pediatr Int*. 2012 Feb;54(1):64-7. doi: 10.1111/j.1442-200X.2011.03505.x. Epub 2011 Dec 22.

19)Hokosaki T, Mori M, Nishizawa T, Nakamura T, Imagawa T, Iwamoto M, Yokota S.:Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. *Pediatr Int*. 2012 Feb;54(1):99-103. doi:10.1111/j.1442-200X.2011.03487.x. Epub 2011 Dec 22.

20)Ozawa R, Inaba Y, Mori M, Hara R, Kikuchi M, Higuchi R, Miyamae T, Imagawa T, Fujiwara T, Saito T, Yokota S:Definitive differences in laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis: systemic arthritis and poly- arthritis. *Modern Rheumatol*. 2012 Aug;22(4): 558-64. Epub 2011 Oct 9.

21)Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, Nerome Y, Iwata N, Murata T, Miyoshi M, Nishimoto N, Kishimoto T.:Safety and efficacy of tocilizumab, an anti-IL-6- receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. *Modern Rheumatol*. 2012:Feb;22(1): 109-15. Epub 2011 Jun 12.

22)Uchimura T, Mori M, Nariai A, Yokota S: Analysis of cases of severe respiratory failure in children with influenza (H1N1) 2009 infection in Japan. *J Infect Chemother*. 2012 Feb;18(1):59-65. Epub 2011 Aug 2

23)横田 俊平, 西小森 隆太, 高田 英俊, 菊地 雅子, 野澤 智, 金高 太一, 木澤 敏毅, 宮前 多佳子, 森 雅亮, 平家 俊男, 原 寿郎, 今川 智之: クリオピリン関連周期性発熱症候群に対する生物学的製剤治療の手引き(2012). カナキヌマブ(総説); 日本小児科学会雑誌(0001-6543)116 巻9号 Page1337-1341(2012.09)

24)野澤 智, 高橋 一夫, 横田 俊平: 若年性皮膚筋炎の皮膚所見(総説) 日本小児皮膚科学会雑誌(0286-9608)31 巻2号 Page93-97,3(2012.06)

25)木澤 敏), 野澤 智, 原 拓磨, 菊地 雅子, 百村 芽衣, 宮前 多佳子, 今川 智之, 横田 俊平, 森 雅亮, 堤 裕幸: TNF 阻害薬が無効で IL-6 阻害薬(トシリズマブ)に変更し改善

をみた難治性多関節型若年性特発性関節炎の 2 例. 臨床リウマチ(0914-8760)24 巻 2 号:146-151(2012.06)

26)横田 俊平:若年性特発性関節炎(JIA)の診断(Q&A).日本医事新報(0385-9215)4611 号 Page56-57(2012.09)

27)森 雅亮, 笠井 和子, 横田 俊平:本邦における不明熱をきたす小児熱性疾患の全国実態調査とアルゴリズム案作成の試み(解説)小児科(0037-4121)53 巻 4 号 Page479-485(2012.04)

(白井 千恵)

著書

1. 白井千恵:線維筋痛症に伴う不眠、うつ状態の薬物療法、線維筋痛症診療ガイドライン 2013、日本線維筋痛症学会編、日本医事新報出版社、東京、2013.
2. 白井千恵:非薬物療法:認知行動療法(CBT),精神療法、心理療法.線維筋痛症診療ガイドライン 2013、日本線維筋痛症学会編、日本医事新報出版社、東京、2013.
3. 白井千恵:慢性疲労症候群と線維筋痛症.野沢胤美編、睡眠医学アトラス検査と臨床、真興交易、東京、2012; 171-176.

雑誌

1. Hatta K, Otachi T, Sudo Y, Kuga H, Takebayashi H, Hayashi H, Ishii R, Kasuya M, Hayakawa T, Morikawa F, Hata K, Nakamura M, Usui C, Nakamura H, Hirata T, Sawa Y; For the JAST study group. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. *Psychiatry Res.* 2012 ; 30;198(2):194-201.
2. Doi N, Hoshi Y, Itokawa M, Yoshikawa T, Ichikawa T, Arai M, Usui C, Tachikawa H. Paradox of schizophrenia genetics: is a paradigm shift occurring? *Behav Brain Funct.* 2012 May 31;8(1):28.
3. Usui C, Hatta K, Aratani S, Yagishita N, Nishioka K, Kanazawa T, Ito K, Yamano Y, Nakamura H, Nakajima T, Nishioka K. The Japanese version of the modified ACR Preliminary Diagnostic Criteria for Fibromyalgia and the Fibromyalgia Symptom Scale: reliability and validity. *Mod Rheumatol.* (in press)
4. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. *Arthritis Res Ther.* 2012 ; 12;14(5):R217
5. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese

patients with fibromyalgia. *Mod Rheumatol.* (in press)

(山野 嘉久)

著書

山野義久：鑑別診断、神経疾患．線維筋痛症診療ガイドライン 2013、日本線維筋痛症学会編、日本医事新報社、東京、2013.

雑誌

1. Sato T., Yamano Y., Tomaru U., Shimizu Y., Ando H., Okazaki T., Nagafuchi H., Shimizu J., Ozaki S., Miyazawa T., Yudoh K., Oka H., Suzuki N. : Serum level of soluble triggering receptor expressed on myeloid cells-1 as a biomarker of disease activity in relapsing polychondritis. *Modern Rheumatology*, in press, 2013.
2. Usui C, Hatta K, Aratani S, Yagishita N, Nishioka K, Kanazawa T, Ito K, Yamano Y, Nakamura H, Nakajima T, Nishioka K.:The Japanese version of the modified ACR Preliminary Diagnostic Criteria for Fibromyalgia and the Fibromyalgia Symptom Scale: reliability and validity. *Modern Rheumatology*, in press, 2012.
3. Yagishita N., Aratani S., Leach C., Amano T., Yamano Y., Nakatani K., Nishioka K. and Nakajima T. :RING-finger type E3 ubiquitin ligase inhibitors as novel candidates for the treatment of rheumatoid arthritis. *Int. J. Mol. Med*, 30:1281-1286, 2012.

(長田 賢一)

著書

長田賢一：薬物療法：向精神薬などの精神科的治療．線維筋痛症ガイドライン 2013、日本線維筋痛症学会編、日本医事新報社、東京、2013.

雑誌

1. 長田賢一、線維筋痛症、こころの科学、83-86, 2013
2. Osada K, Watanabe T, Taguchi A, Ogawa Y, Haga T, Nakano M, Fujiwara K, Yanagida T, Sasuga Y, Psychiatric treatment for fibromyalgia, *Clin Rheumatol*, 24(1): 12-19, 2012

(伊藤 和憲)

著書

1.伊藤和憲：東洋医学的アプローチ：下肢・足の痛み（菊池臣一編）．南江堂，147-159, 2012.

雑誌

1. Itoh K, Asai S, Ohyabu H, Imai K, Kitakoji H.: Effectd of trigger point acupuncture treatment on temporomandibular disorders: A preliminary randomized clinical trial. J Acupunct Meridian Stud, 2012;5(2);57-62.